Physician profile
Analiza P Guerrero
NPI 1972821064
$4,536.09
in general payments reported to CMS, 2019-2025
22 companies · $811 in 2025
The $811 reported for 2025 was more than what 87% of General Practice (Registered Nurse) providers received nationally (typical 2025 total: $110).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $1,031 · 2022: $1,143 · 2023: $953 · 2024: $598 · 2025: $811.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,362.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,361.84 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Vifor Pharma, INC. | $1,024.17 | 2021-2025 | Veltassa |
| Fresenius USA Marketing, INC. | $380.98 | 2021-2025 | Velphoro, Velphoro |
| Novartis Pharmaceuticals Corporation | $363.48 | 2024-2025 | |
| Bayer Healthcare Pharmaceuticals INC. | $344.57 | 2021-2025 | |
| Amgen INC. | $328.19 | 2021-2024 | Parsabiv, Tavneos, Aranesp |
| Aurinia Pharma U.S., INC. | $308.07 | 2021-2025 | Lupkynis |
| Otsuka America Pharmaceutical, INC. | $286.76 | 2021-2025 | Jynarque |
| Akebia Therapeutics INC | $280.53 | 2021-2025 | Vafseo, Auryxia |
| Novo Nordisk INC | $218.44 | 2023-2025 | Wegovy, Rybelsus, Ozempic |
| Ani Pharmaceuticals, INC. | $212.20 | 2023-2025 | Purified Cortrophin Gel |
| Mallinckrodt Hospital Products INC. | $113.84 | 2021-2022 | |
| Ardelyx, INC. | $104.09 | 2023-2025 | Ibsrela |
| Nxstage Medical, INC. | $101.71 | 2023 | Nxstage System One |
| Opko Pharmaceuticals, LLC | $90.51 | 2021-2024 | Rayaldee |
| Astrazeneca Pharmaceuticals Lp | $81.83 | 2021-2022 |
Show all 22 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbott Laboratories | $63.79 | 2023 | Thoratec Heartmate 3 Lvas Implant Kit |
| Travere Therapeutics, INC. | $59.12 | 2023 | |
| Calliditas Therapeutics US INC. | $54.96 | 2024-2025 | Tarpeyo |
| Alexion Pharmaceuticals, INC. | $46.35 | 2021-2022 | |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $36.48 | 2022-2023 | |
| Genentech USA, INC. | $22.13 | 2021 | |
| Glaxosmithkline, LLC. | $13.89 | 2024 | Benlysta |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Analiza Guerrero listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.